Lipids & metabolic liver disease
Integrated Plasma Proteomics and Functional Analyses Reveal Hepatic CDHR2 as a Potential Therapeutic Target in MASLD
Authors' conclusion
These findings identify CDHR2 as a novel regulator of MASLD development and progression, and highlight it as a potential therapeutic target.
Study context
- Population
- UK Biobank participants with MASLD with imaging-derived corrected T1 (cT1) and plasma proteomic data; in vitro FFA-treated primary hepatocytes, HepG2 and AML12 cells
- Outcome
- Proteins associated with cT1, causal effects of candidate proteins on MASLD and cirrhosis (MR), hepatic CDHR2 expression and in vitro function
Methodological detailsplasma proteomics association analysis, two-sample bidirectional Mendelian randomisation, bulk and single-cell RNA-seq, in vitro functional validation
- Plasma proteomics association analysis
- Two-sample bidirectional Mendelian randomisation
- Bulk and single-cell RNA-seq
- In vitro functional validation
Main finding
As reported in the abstract
- Proteins significantly associated with cT1 in patients with fatty liver
- 36
Original publication
Integrated Plasma Proteomics and Functional Analyses Reveal Hepatic CDHR2 as a Potential Therapeutic Target in MASLD. Diabetes Obes Metab. Published 10 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →